Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...

Recce Pharmaceuticals is up ~9% today after reporting positive patient data analysis from its phase II clinical trial of ...

Chemomab Therapeutics (CMMB) announced the successful completion of its End-of-Phase 2 Meeting with the FDA and alignment with FDA on the ...